{"id":"NCT00897104","sponsor":"Organon and Co","briefTitle":"MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)","officialTitle":"A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Compare the Efficacy and Safety of MK0462 5 mg p.o. and Sumatriptan 50 mg p.o. for the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1995-08","primaryCompletion":"1996-05","completion":"1996-09","firstPosted":"2009-05-12","resultsPosted":"2010-07-23","lastUpdate":"2022-02-03"},"enrollment":933,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Headache"],"interventions":[{"type":"DRUG","name":"rizatriptan benzoate (MK0462)","otherNames":["MK0462"]},{"type":"DRUG","name":"Comparator: sumatriptan","otherNames":[]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.","primaryOutcome":{"measure":"Pain Relief at 2 Hours After Treatment","timeFrame":"2 hours after treatment","effectByArm":[{"arm":"Rizatriptan 5 mg","deltaMin":223,"sd":null},{"arm":"Sumatriptan 5 mg","deltaMin":238,"sd":null},{"arm":"Placebo","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19210513","11422095","11284464"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":355},"commonTop":["Asthenia/Fatigue","Nausea","Dizziness","Somnolence","Paresthesia"]}}